• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    483.21 +4.94 (+1.03%)
    Streaming Delayed Price Updated: 3:27 PM EST, Feb 4, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about United Therapeutics Corporation - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at Upcoming Investor Conferences
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports First Quarter 2025 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
    From United Therapeutics Corporation
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.